BioLineRx Ltd. (BLRX)
BLRX Stock Price Chart
Explore BioLineRx Ltd. interactive price chart. Choose custom timeframes to analyze BLRX price movements and trends.
BLRX Company Profile
Discover essential business fundamentals and corporate details for BioLineRx Ltd. (BLRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jul 2011
Employees
28.00
Website
https://www.biolinerx.comCEO
Philip A. Serlin
Description
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
BLRX Financial Timeline
Browse a chronological timeline of BioLineRx Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.15, while revenue estimate is $428.50k.
Earnings released on 27 May 2026
EPS came in at -$0.36 surpassing the estimated -$1.04 by +65.38%, while revenue for the quarter reached $477.00k , beating expectations by +39.07%.
Earnings released on 23 Mar 2026
EPS came in at -$0.27 surpassing the estimated -$0.39 by +29.87%, while revenue for the quarter reached $194.00k , missing expectations by -62.26%.
Earnings released on 24 Nov 2025
EPS came in at -$0.22 surpassing the estimated -$0.41 by +46.34%, while revenue for the quarter reached $427.00k , missing expectations by -36.27%.
Earnings released on 14 Aug 2025
EPS came in at -$1.00 falling short of the estimated -$0.35 by -185.71%, while revenue for the quarter reached $304.00k , missing expectations by -60.86%.
Earnings released on 27 May 2025
EPS came in at $1.39 surpassing the estimated -$0.84 by +265.48%, while revenue for the quarter reached $255.00k , missing expectations by -86.04%.
Earnings released on 25 Mar 2025
EPS came in at $6.00 surpassing the estimated -$4.20 by +242.86%, while revenue for the quarter reached $11.75m , beating expectations by +52.22%.
Stock split effective on 30 Jan 2025
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 25 Nov 2024
EPS came in at -$2.80 falling short of the estimated -$0.05 by -5.50k%, while revenue for the quarter reached $4.94m , missing expectations by -5.51%.
Earnings released on 15 Aug 2024
EPS came in at $0.40 surpassing the estimated -$0.14 by +385.71%, while revenue for the quarter reached $5.39m , beating expectations by +37.23%.
Earnings released on 28 May 2024
EPS came in at -$0.01 surpassing the estimated -$0.29 by +96.55%, while revenue for the quarter reached $6.86m , beating expectations by +0.81%.
Earnings released on 26 Mar 2024
EPS came in at -$0.15 surpassing the estimated -$0.22 by +31.82%, while revenue for the quarter reached $4.80m , beating expectations by +60.00%.
Earnings released on 20 Nov 2023
EPS came in at -$12.00 falling short of the estimated -$7.20 by -66.67%.
Earnings released on 30 Aug 2023
EPS came in at -$12.00 falling short of the estimated -$6.40 by -87.50%.
Earnings released on 24 May 2023
EPS came in at -$6.00 falling short of the estimated -$5.60 by -7.14%.
Earnings released on 22 Mar 2023
EPS came in at -$3.60 surpassing the estimated -$5.60 by +35.71%.
Earnings released on 15 Nov 2022
EPS came in at -$6.00 surpassing the estimated -$6.40 by +6.25%.
Earnings released on 16 Aug 2022
EPS came in at -$6.40 falling short of the estimated -$5.60 by -14.29%.
Earnings released on 11 May 2022
EPS came in at -$4.00 surpassing the estimated -$6.00 by +33.33%.
Earnings released on 16 Mar 2022
EPS came in at -$3.20 surpassing the estimated -$5.60 by +42.86%.
Earnings released on 18 Nov 2021
EPS came in at -$9.20 falling short of the estimated -$5.20 by -76.92%.
Earnings released on 18 Aug 2021
EPS came in at -$6.00 falling short of the estimated -$4.80 by -25.00%.
BLRX Stock Performance
Access detailed BLRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
